AMAL Therapeutics acquired by Boehringer Ingelheim
Share this article
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
Boehringer Ingelheim announced on 15 July 2019 the acquisition of UNIGE’s spin-off, AMAL Therapeutics. This move will enable the family-owned pharmaceutical company to “develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunization platform“.
“Acquiring AMAL is part of Boehringer Ingelheim’s long-term strategy to enhance our existing position as an innovator of novel cancer therapies, including immuno-oncology treatments, which leverage cutting-edge scientific discoveries and their applications,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “We want to pioneer new paradigms of biology-based care for cancer patients, and the technologies and expertise developed at AMAL are critical to our efforts.”